World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
52
Citations
15517
World Ranking
4025
National Ranking
1839

Robert H. Collins publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Robert H. Collins sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 152 publications — 17th percentile

17% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Robert H. Collins D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Robert H. Collins sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 52 D-Index — 19th percentile

19% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Robert H. Collins is affiliated with The University of Texas Southwestern Medical Center in the United States. Their research primarily spans the field of Medicine, with a particular focus on Hematology, Genetics, Molecular Biology, Oncology, and Immunology. This multidisciplinary approach supports investigations into various blood disorders and cancer-related conditions.

The scientist's recent publications address critical topics in leukemia and myeloid malignancies. Notable papers include:

  • Integrative analysis of drug response and clinical outcome in acute myeloid leukemia, 2022, Cancer Cell
  • Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial, 2020, Nature Medicine
  • Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial, 2020, The Lancet Haematology
  • Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML, 2021, Blood
  • Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology, 2024, Journal of the National Comprehensive Cancer Network

Robert H. Collins frequently collaborates with other researchers, including:

  • Yazan F. Madanat
  • Stephen S. Chung
  • Prapti A. Patel
  • Farrukh T. Awan
  • Gurbakhash Kaur

The scientist has contributed extensively to multiple publication venues, reflecting their active role in the hematology and oncology research communities. Key journals featuring their work include:

  • Blood
  • Transplantation and Cellular Therapy
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • Leukemia Research

Their research topics cover a broad spectrum within hematologic malignancies and related therapies. Main topics include:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia research

Best Publications

  • Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

    R H Collins;O Shpilberg;W R Drobyski;D L Porter

  • Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution

    Daniel C Douek;Robert A Vescio;Michael R Betts;Jason M Brenchley

  • Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation

    Kenneth Weinberg;Bruce R. Blazar;Bruce R. Blazar;Bruce R. Blazar;John E. Wagner;John E. Wagner;John E. Wagner;Edward Agura;Edward Agura;Edward Agura

  • Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.

    David L Porter;Robert H Collins;Ofer Shpilberg;William R Drobyski

  • Prospective Trial of Chemotherapy and Donor Leukocyte Infusions for Relapse of Advanced Myeloid Malignancies After Allogeneic Stem-Cell Transplantation

    John E. Levine;Thomas Braun;Samuel L. Penza;Patrick Beatty

  • A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy

    P. L. Amlot;M. J. Stone;D. Cunningham;J. Fay

  • Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program.

    Hugo Castro-Malaspina;Richard E. Harris;James Gajewski;Norma Ramsay

  • LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration

    Mi Deng;Xun Gui;Jaehyup Kim;Li Xie

  • Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.

    Viktoras Frismantas;Maria Pamela Dobay;Anna Rinaldi;Joelle Tchinda

  • Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions

    David L. Porter;Robert H. Collins;Christine Hardy;Nancy A. Kernan

  • Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial

    Stefan Faderl;Meir Wetzler;David Rizzieri;Gary Schiller

  • Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.

    Amy Burd;Ross L. Levine;Amy S. Ruppert;Alice S. Mims

  • Marrow Transplants From Unrelated Donors for Patients With Aplastic Anemia: Minimum Effective Dose of Total Body Irradiation

    H. Joachim Deeg;H. Joachim Deeg;Michael D. Amylon;Richard E. Harris;Robert Collins

  • Prospective Trial of Chemotherapy and Donor Leukocyte Infusions for Relapse of Advanced Myeloid Malignancies After Allogeneic Stem-Cell Transplantation

    Unknown

  • Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation

    Jaroslav Michálek;Robert H Collins;Brenna J Hill;Jason M Brenchley

  • The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development

    Xunlei Kang;Zhigang Lu;Changhao Cui;Changhao Cui;Mi Deng

  • Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor β loci sequences

    Jaroslav Michalek;Robert H. Collins;Humdum P. Durrani;Petra Vaclavkova

  • Brief report: Donor-derived long-term multilineage hematopoiesis in a liver-transplant recipient

    Robert H. Collins;John Anastasi;Leon W M M Terstappen;Afzal Nikaein

  • Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy.

    H. Joachim Deeg;Kristy Seidel;Jim Casper;Claudio Anasetti

  • Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia

    Hanna J. Khoury;Robert H. Collins;William Blum;Patrick S. Stiff

  • Graft-versus-Host Disease in a Liver Transplant Recipient

    Robert H. Collins;Barry Cooper;Afzal Nikaein;Goran Klintmalm

  • Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population

    J. E. Levine;A. J. Barrett;M. J. Zhang;M. Arora

  • Bootstrap Benefit Segmentation as an Experiential Learning Activity

    John A. Schibrowsky;Robert H. Collins;James W. Peltier

  • Elucidating Mechanisms of Acquired Resistance to IDH Inhibition By Saturation Variant Screening of Base-Edited Leukemia Cells

    Junhua Lyu;Yuxuan Liu;Hui Cao;Mingyi Chen

  • The appearance of alloreactive T cell clones correlates withclinical GVHD in patients undergoing allogeneic stem celltransplants

    Jaroslav Michálek;Robert H. Collins;Humdum P. Durrani;Daniel C. Douek

Frequent Co-Authors

Michael R. Betts
Michael R. Betts University of Pennsylvania
Bruce R. Blazar
Bruce R. Blazar University of Minnesota
Richard A. Koup
Richard A. Koup National Institute of Allergy and Infectious Diseases
John E. Wagner
John E. Wagner University of Minnesota
Rolando R. Garcia
Rolando R. Garcia National Center for Atmospheric Research
Kenneth I. Weinberg
Kenneth I. Weinberg Stanford University
Ellen S. Vitetta
Ellen S. Vitetta The University of Texas Southwestern Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related online degrees can open various career pathways in healthcare and research. Nurses aiming to deepen their expertise might consider transitioning their focus, such as moving from an FNP to ACNP role. This shift allows for specialization in acute care settings, broadening clinical responsibilities and impact. Learn more about making this career move with the fnp to acnp guide.

Accelerated educational programs are particularly valuable for individuals seeking to fast-track their careers. For example, accelerated nurse practitioner programs offer intensive curriculums that prepare students quickly for advanced clinical roles. These programs are well-suited for those looking to enter the workforce without lengthy delays.

For students coming from non-nursing backgrounds, there are online paths tailored to making this transition smoother. The availability of online accelerated nursing programs for non nurses provides a flexible and efficient way to become qualified nurses, opening doors to immunology-related clinical roles.

Additionally, when beginning a nursing career, it's important to find programs with accessibly high acceptance rates. ABSN programs with high acceptance rates offer opportunities for many students to enter the nursing field and eventually specialize in areas like immunology or nurse practitioner roles.

Best Scientists Citing Robert H. Collins

Trending Scientists

Recently Published Articles